Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.07. | Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone | 2 | GlobeNewswire (USA) | ||
14.07. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin | 158 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part... ► Artikel lesen | |
03.07. | Karolinska Development AB (publ): Karolinska Development receives update from Organon concerning OG-6219 | 11 | GlobeNewswire (USA) | ||
KAROLINSKA DEVELOPMENT Aktie jetzt für 0€ handeln | |||||
30.06. | Karolinska Development AB (publ): Karolinska Development divests shares in portfolio company OssDsign | 161 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company's... ► Artikel lesen | |
27.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million | 1 | GlobeNewswire (USA) | ||
04.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets | 36 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding... ► Artikel lesen | |
26.05. | Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study | 1 | GlobeNewswire (USA) | ||
15.05. | Karolinska Development AB (publ): Karolinska Development's Annual General Meeting 2025 | 2 | GlobeNewswire (USA) | ||
13.05. | Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US | 2 | GlobeNewswire (USA) | ||
07.05. | Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 2025 | 1 | GlobeNewswire (USA) | ||
05.05. | Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation | 225 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - May 5, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been awarded a research grant by The Michael J.... ► Artikel lesen | |
30.04. | Karolinska Development AB (publ): Karolinska Development portfolio company OssDsign will change CEO during second half of 2025 | 3 | GlobeNewswire (USA) | ||
30.04. | Karolinska Development AB (publ): Interim Report - January-March 2025 | 105 | GlobeNewswire (Europe) | STOCKHOLM - 30 April 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-March 2025. The full report is available on the Company's website. "Developmental... ► Artikel lesen | |
07.04. | Notice of Annual General Meeting in Karolinska Development AB (publ) | 1 | GlobeNewswire (USA) | ||
01.04. | Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition appoints new CEO | 227 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) annouces that Viktor Drvota today takes over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota... ► Artikel lesen | |
21.03. | Karolinska Development AB (publ): Karolinska Development Annual Report 2024 published | 2 | GlobeNewswire (USA) | ||
18.03. | Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study | 250 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical... ► Artikel lesen | |
13.03. | Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01 | 399 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an... ► Artikel lesen | |
12.03. | Karolinska Development AB (publ): Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial | 201 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug... ► Artikel lesen | |
25.02. | Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01 | 149 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GSK | 15,585 | +0,06 % | Dividenden-Garant GSK: Massiver Rückschlag | Bittere Pille für das Pharma-Unternehmen GSK auf dem Weg zur US-Zulassung für den großen Hoffnungsträger Blenrep: Ein Berater-Gremium der amerikanischen Zulassungsbehörde FDA hat ein negatives Votum... ► Artikel lesen | |
MERCK KGAA | 108,95 | -0,77 % | Aktienmarkt: Aktie von Merck tritt auf der Stelle (109,85 €) | Der Kurs der dem Anteilsschein von Merck kommt kaum von der Stelle. Der jüngste Kurs betrug 109,85 Euro. Der Kurs der Aktie von Merck zeigt sich aktuell kaum verändert im Vergleich zu der letzten Notierung... ► Artikel lesen | |
BAYER | 27,805 | +0,91 % | Bayer, NetraMark, Evotec: Wie KI-Forschung jetzt Renditen beschleunigt und Ihr Depot optimieren könnte | Die Gesundheitsbranche wird 2025 von KI und Technologien radikal umgekrempelt. Während Pharmariesen unter Kostendruck und regulatorischen Stürmen ächzen revolutionieren Algorithmen die Arzneimittelentwicklung:... ► Artikel lesen | |
NOVO NORDISK | 56,88 | +3,12 % | Novo Nordisk: Kommt eine Gewinnwarnung? | Am 6. August wird Novo Nordisk Zahlen zum zweiten Quartal publizieren. Die Analysten der UBS glauben, dass die Dänen mit den Zahlen ihre Prognose für 2025 zurücknehmen werden. Hier spielen vor allem... ► Artikel lesen | |
PFIZER | 21,365 | -0,07 % | Bristol Myers Squibb, Pfizer Announce Direct-to-patient Option For Eliquis | NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) and Pfizer (PFE) Thursday announced a direct-to-patient option for purchasing their blood thinner medicine, Eliquis through the partnership's... ► Artikel lesen | |
SANOFI | 83,39 | +0,14 % | Thermo Fisher übernimmt Sterilproduktion von Sanofi in den USA | Der US-Laborausrüster Thermo Fisher Scientific erweitert seine Produktionsinfrastruktur und übernimmt die Sterilfabrik von Sanofi im US-Bundesstaat New Jersey. Das Werk in Ridgefield soll künftig das... ► Artikel lesen | |
ELI LILLY | 660,60 | +0,87 % | Eli Lilly: Warten auf Impulse | In den letzten Wochen zeigte die Aktie eines der bedeutendsten Pharmaunternehmen der Welt auffallend wenig Bewegung Den vollständigen Artikel lesen ... ► Artikel lesen | |
ROCKET LAB | 40,000 | 0,00 % | Rocket Lab's first hurdle to flying its new rocket is getting it to the pad | ||
ASTRAZENECA | 119,60 | +1,10 % | Buy or Goodbye?: Meta, Hensoldt, Astrazeneca und Thyssenkrupp - Die Analystenstimmen des Tages | © Foto: Britta Pedersen/zb/dpaMeta, Hensoldt, Astrazeneca und Thyssenkrupp: So bewerten Top-Analysten die Aktien. Ein Überblick.Jefferies hebt das Kursziel für Meta an Das Analysehaus Jefferies hat... ► Artikel lesen | |
TILRAY BRANDS | 0,660 | -0,84 % | Tilray stock pops 15%: should you sell TLRY shares into the strength? | ||
MERCK & CO | 69,60 | +0,14 % | Veeva Systems: Merck Commits to Veeva Vault CRM | Deep application provides foundation for commercial execution
PLEASANTON, Calif., July 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known... ► Artikel lesen | |
MEDPACE | 406,70 | +0,07 % | Medpace Holdings, Inc. - 10-Q, Quarterly Report | ||
SCHOTT PHARMA | 24,650 | -1,99 % | Schott Pharma-Aktie legt um 0,58 Prozent zu (25,90 €) | Die Schott Pharma-Aktie notiert heute fester. Zuletzt zahlten Investoren für das Wertpapier 25,90 Euro. Ein Kursplus von 0,58 Prozent steht gegenwärtig für das Wertpapier von Schott Pharma zu Buche.... ► Artikel lesen | |
METSERA | 39,520 | -0,98 % | Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i | Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated... ► Artikel lesen | |
CANOPY GROWTH | 1,066 | +0,76 % | Canopy Growth: Buy, Sell, or Hold in July 2025? |